文献速递心外重症与机械循环支持

重度COVID-19静脉-静脉体外膜氧合支持的一年结局

One-Year Outcomes With Venovenous Extracorporeal Membrane Oxygenation Support for Severe COVID-19.
PubMed 文献 · Ann Thorac Surg · 2022-03-10

单中心回顾性研究纳入2020年3月10日至5月1日因重度COVID-19接受静脉-静脉体外膜氧合(VV-ECMO)支持的30例患者,出院存活率为90%(27/30)。中位随访10.8个月时生存率为86.7%,出院患者中44.4%完成肺功能检查,中位预测用力呼气量百分比为100%。

要点

  • 30例重度COVID-19患者接受VV-ECMO支持,27例(90%)存活出院。
  • 中位随访10.8个月时生存率86.7%,包括1例接受肺移植的患者。
  • 出院患者中44.4%完成肺功能检查,中位预测FEV1百分比为100%。

核心结论

  • 对重度COVID-19患者采用明确规定的VV-ECMO患者选择与管理策略,实现了优异的出院存活率,且该存活率在ECMO置管后1年得以维持。

研究设计与样本

  • 单机构回顾性综述,纳入2020年3月10日至2020年5月1日期间因重度COVID-19置管接受VV-ECMO的所有患者,由多学科ECMO团队评估、选择和管理。
  • 主要结局为出院存活率,同时报告可获得的1年随访数据。

主要发现

  • 共30例患者接受VV-ECMO支持,27例(90%)存活出院。
  • 所有患者出院回家或转至急性康复机构时均使用室内空气,仅1例(3.7%)需要补充氧疗。
  • 自ECMO置管起中位随访10.8个月(四分位距[IQR] 8.9-14.4个月)时,生存率为86.7%,包括1例接受肺移植的患者。
  • 出院患者中44.4%(12/27)进行了肺功能检查,中位预测用力呼气量百分比为100%(IQR 91%-110%)。
  • 存活者中59.3%(16/27)进行了6分钟步行试验,中位值为350 m(IQR 286-379 m)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Severe coronavirus disease 2019 (COVID-19) can cause acute respiratory failure requiring mechanical ventilation. Venovenous (VV) extracorporeal membrane oxygenation (ECMO) has been used in patients in whom conventional mechanical ventilatory support has failed. To date, published data have focused on survival from ECMO and survival to discharge. In addition to survival to discharge, this study reports 1-year follow-up data for patients who were successfully discharged from the hospital. METHODS: A single-institution, retrospective review of all patients with severe COVID-19 who were cannulated for VV-ECMO between March 10, 2020 and May 1, 2020 was performed. A multidisciplinary ECMO team evaluated, selected, and managed patients with ECMO support. The primary outcome of this study was survival to discharge. Available 1-year follow-up data are also reported. RESULTS: A total of 30 patients were supported with VV-ECMO, and 27 patients (90%) survived to discharge. All patients were discharged home or to acute rehabilitation on room air, except for 1 patient (3.7%), who required supplemental oxygen therapy. At a median follow-up of 10.8 months (interquartile range [IQR], 8.9-14.4 months) since ECMO cannulation, survival was 86.7%, including 1 patient who underwent lung transplantation. Of the patients discharged from the hospital, 44.4% (12/27) had pulmonary function testing, with a median percent predicted forced expiratory volume of 100% (IQR, 91%-110%). For survivors, a 6-minute walk test was performed in 59.3% (16/27), with a median value of 350 m (IQR, 286-379 m). CONCLUSIONS: A well-defined patient selection and management strategy of VV-ECMO support in patients with severe COVID-19 resulted in exceptional survival to discharge that was sustained at 1-year after ECMO cannulation.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Smith DE, Chang SH, Geraci TC, et al. One-Year Outcomes With Venovenous Extracorporeal Membrane Oxygenation Support for Severe COVID-19. Ann Thorac Surg. 2022. PMID: 35282865. doi:10.1016/j.athoracsur.2022.01.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。